Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

• Formula: C18h31n5o9
• EINECS: N/a
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Crude
• Colour: White
• Transport Package: 10 Vials Per Box
• Specification: Powder
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 8501109190
• Production Capacity: 4000g Per Month

Product Description

1. Product Basic Information

Product name	Livagen(Lys-Glu-Asp-Ala)
CAS No.	N/A
MF	C18H31N5O9
MW	461.47

2. Product Introduction
It is stated that Livagen (Lys-Glu-Asp-Ala) is a weakly hydrolyzed peptide. Peptide hydrolases of small intestine do not hydrolyze Livagen even to a small extent. Under in vitro conditions Livagen reduces glycil-L-leucinedipeptidase activity in small intestine by 50%.Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in chromosomes. Our results indicate that Livagen causes de-heterochromatinization (activation) of chromatin, which is realized via modification of heterochromatin and heterochromatinized regions in chromosomes from old people.Livagen proved to be more efficient also as compared to well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM. The dose-inhibitory effect curves for Livagen and Epitalon were plotted; their IC50 equaled 20 and 500 microM, respectively.